Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences-Reference-Cited by-同舟云学术

Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences

Published:2003-01 Issue:4 Volume:6 Page:432-438
ISSN:1472-6483
Container-title:Reproductive BioMedicine Online
language:en
Short-container-title:Reproductive BioMedicine Online

Author:

Olivennes F,Diedrich K,Frydman R,Felberbaum RE,Howles CM

Publisher

Elsevier BV

Subject

Developmental Biology,Reproductive Medicine,Obstetrics and Gynecology

Reference28 articles.

1. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group;Albano;Human Reproduction,2000

2. GnRH antagonists in assisted reproduction: a Cochrane Review;Al-Inany;Human Reproduction,2002

3. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial

4. The role of LHRH agonists and antagonists;Chillik;Reproductive BioMedicine Online,2001

5. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation;European and Middle East Orgalutran® Study Group;Human Reproduction,2001

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The place of GnRH antagonists in modern ART programs: the possibilities of using of new drug of ganirelix;Russian Journal of Human Reproduction;2024

2. GnRH Antagonist Protocol With Cessation of Cetrorelix on Trigger Day Improves Embryological Outcomes for Patients With Sufficient Ovarian Reserve;Frontiers in Endocrinology;2021-10-14

3. In vitro prediction of in vivo pseudo-allergenic response via MRGPRX2;Journal of Immunotoxicology;2021-01-01

4. Antral follicle responsiveness assessed by follicular output RaTe(FORT) correlates with follicles diameter;Journal of Ovarian Research;2019-05-25

5. Role of Antagonists in Human IVF: The Tool for a Safer and More Patient Friendly IVF;Handbook of In Vitro Fertilization;2017-03-31